Over the coming months, Citron Research will release a series of articles on Questcor Pharmaceuticals Inc (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”. These articles will dig deeper into topics such as:
- The Chronic Disease Fund, and the role it plays in contributing to Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s revenues
- Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)
- Insurance reimbursement coding for Acthar
Meanwhile, today’s question is whether Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s Synacthen acquisition is anti-competitive. The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.
We are sure that Questcor Pharmaceuticals Inc (NASDAQ:QCOR) will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel. This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.
Historically, the Chinese market has been relatively isolated from international investors, but much is changing there now, making China virtually impossible for the diversified investor to ignore. Earlier this year, CNBC pointed to signs that Chinese regulators may start easing up on their scrutiny of companies after months of clamping down on tech firms. That Read More
See full PDF here.
Questcor Update Final by ValueWalk.com